Home
NNVC
NNVC News

Latest NanoViricides Inc. (NNVC) News on January 19, 2025

ACCESS Newswire

6 days ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

ACCESSWIRE

11 days ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

ACCESSWIRE

a month ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

ACCESSWIRE

2 months ago

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ACCESSWIRE

2 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Associated Press Finance

2 months ago

NanoViricides: Fiscal Q1 Earnings Snapshot

ACCESSWIRE

2 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

ACCESSWIRE

3 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

ACCESSWIRE

3 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy

Insider Monkey

3 months ago

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy

ACCESSWIRE

3 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

ACCESSWIRE

4 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

ACCESSWIRE

4 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

ACCESSWIRE

5 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

ACCESSWIRE

5 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

ACCESSWIRE

5 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Newsfile

6 months ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

ACCESSWIRE

6 months ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy

Zacks Small Cap Research

6 months ago

NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy

ACCESSWIRE

6 months ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

ACCESSWIRE

6 months ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

ACCESSWIRE

7 months ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

7 months ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

7 months ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

ACCESSWIRE

7 months ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

ACCESSWIRE

8 months ago

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

ACCESSWIRE

8 months ago

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

ACCESSWIRE

8 months ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

Associated Press Finance

8 months ago

NanoViricides: Fiscal Q3 Earnings Snapshot

NanoViricides Has Filed its Quarterly Report

ACCESSWIRE

8 months ago

NanoViricides Has Filed its Quarterly Report

A Novel Broad-Spectrum Antiviral with Activity Against RSV

ACCESSWIRE

8 months ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

ACCESSWIRE

8 months ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

ACCESSWIRE

8 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

ACCESSWIRE

8 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

ACCESSWIRE

9 months ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

ACCESSWIRE

a year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Associated Press Finance

a year ago

NanoViricides: Fiscal Q2 Earnings Snapshot

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

ACCESSWIRE

a year ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

ACCESSWIRE

a year ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

ACCESSWIRE

a year ago

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

PR Newswire

a year ago

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

GlobeNewswire

a year ago

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

Duos Secures $2.4 Million AI Subscription and Services Agreement

GlobeNewswire

a year ago

Duos Secures $2.4 Million AI Subscription and Services Agreement

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

GlobeNewswire

a year ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Business Wire

a year ago

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

GlobeNewswire

a year ago

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Business Wire

a year ago

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Synlogic Provides Corporate Update and Outlook for 2024

GlobeNewswire

a year ago

Synlogic Provides Corporate Update and Outlook for 2024

NanoViricides to Present at the Biotech Showcase in San Fransisco

ACCESSWIRE

a year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Comstock (LODE) Executes First Commercial Biorefinery Deal

Zacks

a year ago

Comstock (LODE) Executes First Commercial Biorefinery Deal

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Business Wire

a year ago

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

GlobeNewswire

a year ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Lipocine to Present at Biotech Showcase 2024

PR Newswire

a year ago

Lipocine to Present at Biotech Showcase 2024

Spectaire Launches AireCore™ Into the Oil and Gas Sector

GlobeNewswire

a year ago

Spectaire Launches AireCore™ Into the Oil and Gas Sector

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

Business Wire

a year ago

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

NextCure Provides Year-End Clinical Pipeline Updates

GlobeNewswire

a year ago

NextCure Provides Year-End Clinical Pipeline Updates

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Business Wire

a year ago

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Life Science Investor Forum Agenda Announced for December 14th, 2023

GlobeNewswire

a year ago

Life Science Investor Forum Agenda Announced for December 14th, 2023

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

GlobeNewswire

a year ago

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

GlobeNewswire

a year ago

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

News Direct

a year ago

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

PR Newswire

a year ago

MultiMetaVerse Announces Updates of the Taomee Acqusition and Termination of Prior Acquisition Agreement

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

ACCESSWIRE

a year ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

PR Newswire

a year ago

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

Zacks

a year ago

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

ACCESSWIRE

a year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

Associated Press Finance

a year ago

NanoViricides: Fiscal Q1 Earnings Snapshot

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

ACCESSWIRE

a year ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

Investcorp Credit Management BDC, Inc. Announces Financial Results for the Quarter Ended September 30, 2023, and Quarterly and Supplemental Distribution

PR Newswire

a year ago

Investcorp Credit Management BDC, Inc. Announces Financial Results for the Quarter Ended September 30, 2023, and Quarterly and Supplemental Distribution

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Arogo Capital Acquisition Corp. Announces Termination of Merger Agreement with EON Reality, Inc.

All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR

PR Newswire

a year ago

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR

Superior Industries International Inc (SUP) Reports Q3 2023 Financial Results

GuruFocus.com

a year ago

Superior Industries International Inc (SUP) Reports Q3 2023 Financial Results

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

GlobeNewswire

a year ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Share on Social Networks: